A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Completed · Phase 1, Phase 2 · NCT03400332
Conditions: Cancer, Melanoma
At a glance
- Research payments reported, 2025
- $2,213
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 281
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986253 (drug), Nivolumab (biological), Ipilimumab (biological), Placebo (other)
- Dates
- Started 2018-02-12; completion 2025-12-04
- Results posted
- Yes
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
From ClinicalTrials.gov, last updated 2026-02-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $2,213 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Texas Onco Southwest Fort Worth $2,213
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.